



Novel Vaccine Approaches for Emerging RNA Viruses

Guest Editor:

Dr. David Beckham

Division of Infectious Diseases,
Departments of Medicine and
Immunology & Microbiology,
University of Colorado Anschutz
Medical Campus, Aurora, CO
80045, USA

Deadline for manuscript
submissions:
closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

Emerging RNA viruses continue to pose a unique threat to global human health. This special issue seeks manuscripts that evaluate new approaches to develop vaccine technology in the field of emerging RNA viruses. These approaches can include basic proof-of-concept approaches for vaccine development, novel adjuvant approaches, immunology of vaccine approaches, and translational efforts to evaluate immunogenicity and efficacy of a vaccine approach for emerging RNA viruses. We are particularly interested in manuscripts that evaluate novel platforms for rapid vaccine development. A continued and persistent effort to develop novel vaccine candidates and approaches for a variety of RNA viruses will provide an important pipeline of data as new RNA viruses emerge and threaten global human health in the future.

Dr. David Beckham
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com